Author

Eivind Valen Egeland

Oslo University HospitalORCID 0000-0002-7273-7277Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cell-cell communication· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Gordon Brent MillsiD· 2 shared Gunhild Mari MælandsmoiD· 2 shared Lina PrasmickaiteiD· 2 shared Mads Haugland HaugeniD· 2 shared Olav EngebraateniD· 2 shared Allison CreasoniD· 1 shared Alvaro Köhn‐LuqueiD· 1 shared Amanda PoissonnieriD· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Gordon Brent MillsORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyFrontiers in OncologyPeer-reviewedMay 4, 2026

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade

Ieva Ailte, Sudhir Kumar Chauhan, Lina Prasmickaite…·Eivind Valen Egeland

This study identifies CD38hiCD19dim cells in lymph nodes as a prognostic marker for improved outcomes in stage III melanoma patients receiving PD-1 blockade.

1 citation

humanbulk RNA-seq

Cancer BiologybioRxivPreprintOct 9, 2025

Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response

Maria Aanesland Dahle, Jan-Lukas Førde, Eivind Valen Egeland…·Mads Haugland Haugen

This study examines how the spatial organization of the tumor-immune microenvironment changes during treatment in ER-positive breast cancer and links these changes to clinical response.

DOI 10.1101/2025.10.09.681336

humanbulk RNA-seq

BioinformaticsbioRxivPreprintSep 7, 2023

Explainable Machine Learning Reveals the Role of the Breast Tumor Microenvironment in Neoadjuvant Chemotherapy Outcome

Youness Azimzade, Mads Haugland Haugen, Xavier Tekpli…·Alvaro Köhn‐Luque

The paper uses scRNA-seq and explainable machine learning to analyze how tumor microenvironment cell types affect neoadjuvant chemotherapy outcomes in breast cancer.

4 citations

humanscRNA-seq